{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:32Z","timestamp":1791410792301,"version":"4.3.3"},"reference-count":22,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Stereotactic radiotherapy (SRT) has become integral to modern oncology, offering the ability to deliver ablative doses while minimizing damage to surrounding normal tissues. Recent advancements in imaging integration, treatment planning, and dose delivery have expanded their clinical applications across various tumor types. However, challenges such as toxicity in anatomically critical regions, optimal margin determination, and the lack of standardized protocols persist. This review explores key issues in contemporary practice and highlights emerging clinical evidence across lung, liver, prostate, brain, and oligometastatic diseases. Further refinement in patient selection and treatment strategies is essential to maximize therapeutic efficacy and ensure safe implementation in broader clinical settings.<\/jats:p>","DOI":"10.1177\/15330338251333658","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T03:09:21Z","timestamp":1743736161000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Exploring the Current Challenges and Pioneering Clinical Applications of Stereotactic Radiotherapy in Cancer Treatment"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4393-1828","authenticated-orcid":false,"given":"Atsuto","family":"Katano","sequence":"first","affiliation":[{"name":"The University of Tokyo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241229363"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.06.002"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.019"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107281"},{"issue":"9","key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jtho.2024.05.366","article-title":"Stereotactic body radiotherapy for centrally located inoperable early-stage NSCLC: EORTC 22113-08113 LungTech phase II trial results","volume":"19","author":"Levy A","year":"2024","unstructured":"Levy A, Adebahr S, Hurkmans C, et al. Stereotactic body radiotherapy for centrally located inoperable early-stage NSCLC: EORTC 22113-08113 LungTech phase II trial results. J Thorac Oncol. 2024;19(9):1297-1309. doi:https:\/\/doi.org\/10.1016\/j.jtho.2024.05.366","journal-title":"J Thorac Oncol"},{"issue":"12","key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.jtho.2024.09.1386","article-title":"Appropriate use criteria (AUC) for non-small cell lung cancer in a central\/ultra-central location: Executive summary of the American radium society's systematic review and guidelines","volume":"19","author":"Park HS","year":"2024","unstructured":"Park HS, Rimner A, Amini A, et al. Appropriate use criteria (AUC) for non-small cell lung cancer in a central\/ultra-central location: Executive summary of the American radium society's systematic review and guidelines. J Thorac Oncol. 2024;19(12):1640-1653. doi:https:\/\/doi.org\/10.1016\/j.jtho.2024.09.1386","journal-title":"J Thorac Oncol"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241235058"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"100217","DOI":"10.1016\/j.tipsro.2023.100217","article-title":"Novel breath-hold liver target stereotactic ablative radiotherapy using the intrafraction diaphragm registration of kilovoltage projection streaming image with digitally reconstructed radiography of the planning computed tomography","volume":"27","author":"Katano A","year":"2023","unstructured":"Katano A, Nozawa Y, Minamitani M, Yamashita H, Nakagawa K. Novel breath-hold liver target stereotactic ablative radiotherapy using the intrafraction diaphragm registration of kilovoltage projection streaming image with digitally reconstructed radiography of the planning computed tomography. Tech Innov Patient Support Radiat Oncol. 2023;27:100217. doi:https:\/\/doi.org\/10.1016\/j.tipsro.2023.100217","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"issue":"11","key":"e_1_3_3_10_2","article-title":"Intrafractional diaphragm variations during breath-hold stereotactic body radiotherapy for a liver tumor based on real-time registration between kilovoltage projection streaming and digitally reconstructed radiograph images: A case report","volume":"15","author":"Katano A","year":"2023","unstructured":"Katano A, Nozawa Y, Minamitani M, Ohira S, Nakagawa K. Intrafractional diaphragm variations during breath-hold stereotactic body radiotherapy for a liver tumor based on real-time registration between kilovoltage projection streaming and digitally reconstructed radiograph images: A case report. Cureus. 2023;15(11):e48188. doi:https:\/\/doi.org\/10.7759\/cureus.48188","journal-title":"Cureus"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-022-02005-1"},{"issue":"15","key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As N","year":"2024","unstructured":"van As N, Griffin C, Tree A, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med. 2024;391(15):1413-1425. doi:https:\/\/doi.org\/10.1056\/NEJMoa2403365","journal-title":"N Engl J Med."},{"issue":"9","key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1200\/JCO-24-01532","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for recurrent small hepatocellular carcinoma: A randomized, open-label, controlled trial","volume":"43","author":"Xi M","year":"2025","unstructured":"Xi M, Yang Z, Hu L, et al. Radiofrequency ablation versus stereotactic body radiotherapy for recurrent small hepatocellular carcinoma: A randomized, open-label, controlled trial. J Clin Oncol. 2025;43(9):1073-1082. doi:https:\/\/doi.org\/10.1200\/jco-24-01532","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: The NRG oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"Dawson LA","year":"2025","unstructured":"Dawson LA, Winter KA, Knox JJ, et al. Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: The NRG oncology\/RTOG 1112 phase 3 randomized clinical trial. JAMA Oncol. 2025;11:136-144. doi:https:\/\/doi.org\/10.1001\/jamaoncol.2024.5403","journal-title":"JAMA Oncol"},{"issue":"6","key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3892\/ol.2022.13311","article-title":"Brain metastasis: Recent treatment modalities and future-perspectives","volume":"23","author":"Katano A","year":"2022","unstructured":"Katano A, Yamashita H. Brain metastasis: Recent treatment modalities and future-perspectives. Oncol Lett. 2022;23(6):191. doi:https:\/\/doi.org\/10.3892\/ol.2022.13311","journal-title":"Oncol Lett"},{"issue":"6","key":"e_1_3_3_16_2","article-title":"Response assessment criteria for brain metastases: Proposal from the RANO group","volume":"16","author":"Lin NU","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H, et al. Response assessment criteria for brain metastases: Proposal from the RANO group. Lancet Oncol. 2015;16(6):e270-e278. doi:https:\/\/doi.org\/10.1016\/s1470-2045(15)70057-4","journal-title":"Lancet Oncol"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70061-0"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241273324"},{"issue":"25","key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma DA","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830-2838. doi:https:\/\/doi.org\/10.1200\/JCO.20.00818","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30537-4"},{"issue":"10422","key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","article-title":"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study","volume":"403","author":"Tsai CJ","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study. Lancet. 2024;403(10422):171-182.","journal-title":"Lancet"},{"issue":"10","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1007\/s12094-023-03170-0","article-title":"Local treatment in oligometastasis from breast cancer: An overview","volume":"25","author":"Burgaleta AM","year":"2023","unstructured":"Burgaleta AM, Burguete AB, Guti\u00e9rrez LR, Nu\u00edn EB, Felipe GA, de la Vega FA. Local treatment in oligometastasis from breast cancer: An overview. Clin Transl Oncol. 2023;25(10):2861-2867.","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.prro.2023.04.014","article-title":"Full dose SBRT in combination with mediastinal chemoradiation for locally advanced, non-small cell lung cancer: A practical guide for planning, dosimetric results from a phase 2 study, and a treatment planning guide for the phase 3 NRG oncology LU-008 trial","volume":"13","author":"Heinzerling JH","year":"2023","unstructured":"Heinzerling JH, Pen OV, Robinson M, et al. Full dose SBRT in combination with mediastinal chemoradiation for locally advanced, non-small cell lung cancer: A practical guide for planning, dosimetric results from a phase 2 study, and a treatment planning guide for the phase 3 NRG oncology LU-008 trial. Pract Radiat Oncol. 2023;13(6):531-539.","journal-title":"Pract Radiat Oncol"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338251333658","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338251333658","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338251333658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:16:21Z","timestamp":1777702581000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338251333658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":22,"alternative-id":["10.1177\/15330338251333658"],"URL":"https:\/\/doi.org\/10.1177\/15330338251333658","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/15330338251333658\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251333658\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251333658\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251333658\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251333658\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251333658\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251333658\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"article-number":"15330338251333658"}}